Autifony Therapeutics Ltd
Autifony Therapeutics is an independent UK based biotechnology company formed in 2011 as a spinout from GSK, which retains equity in the company. The Company is focused on the development of high value, novel medicines to treat serious diseases of the central nervous system. It is funded by SV Life Sciences, Touchstone Innovations plc, Pfizer Venture Investments, International Biotechnology Trust PLC, and UCL Business plc.
Year founded: 2011